Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Equity Average (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Equity Average for 10 consecutive years, with $709.9 million as the latest value for Q4 2025.

  • Quarterly Equity Average fell 22.61% to $709.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $709.9 million through Dec 2025, down 22.61% year-over-year, with the annual reading at $771.7 million for FY2025, 19.71% down from the prior year.
  • Equity Average for Q4 2025 was $709.9 million at Intellia Therapeutics, down from $731.8 million in the prior quarter.
  • The five-year high for Equity Average was $1.2 billion in Q1 2023, with the low at $520.3 million in Q2 2021.
  • Average Equity Average over 5 years is $907.5 million, with a median of $942.1 million recorded in 2024.
  • The sharpest move saw Equity Average soared 150.66% in 2021, then decreased 25.51% in 2025.
  • Over 5 years, Equity Average stood at $1.1 billion in 2021, then fell by 4.04% to $1.0 billion in 2022, then grew by 1.31% to $1.0 billion in 2023, then dropped by 12.12% to $917.3 million in 2024, then fell by 22.61% to $709.9 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $709.9 million, $731.8 million, and $747.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.